Refractory Tumor clinical trials at UCSF

1 research study open to eligible people

Showing trials for

  • 9-ING-41 in Pediatric Patients with Refractory Malignancies.

    open to eligible people ages up to 22 years

    9-ING-41 has anti-cancer clinical activity with no significant toxicity in adult patients. This Phase 1 study will study its efficacy in paediatric patients with advanced malignancies.

    San Francisco, California and other locations

Our lead scientists for Refractory Tumor research studies include .

Last updated: